Trial Profile

Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
Indications Solid tumours
Focus Adverse reactions
Sponsors Regeneron Pharmaceuticals; Sanofi

Most Recent Events

09 Jan 2013 Status changed from recruiting to completed.
11 Jun 2008 New trial record.
06 Jun 2008 Results were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com